Skip to main content
. 2005 Feb 14;144(8):1017–1028. doi: 10.1038/sj.bjp.0706153

Table 1.

Comparison of the properties of LMWH, fondaparinux and idraparinux

Feature LMWH Fondaprinux Idraparinux
Mode of administration Subcutaneous Subcutaneous Subcutaneous
Bioavailability 80–90% 100% 100%
Half-life (h) 4 17 80
Target Factor Xa and thrombin Factor Xa Factor Xa
Renal clearance Yes Yes Yes
Neutralized by protamine sulfate Partial No No